The Preeclampsia Diagnostics Market size was valued at USD 1.07 Billion in 2022 and is expected to reach USD 1.24 Billion By 2030 and grow at a CAGR of 2.4% over the forecast period of 2023-2030.
Preeclampsia is a pregnancy-related condition characterised by elevated blood pressure and organ damage, most frequently affecting the liver and kidneys. The market for diagnostic tests and tools used to identify and keep track of preeclampsia is referred to as the "preeclampsia diagnostics market". Both the mother and the unborn are at risk from the potentially severe disease known as preeclampsia.
.png)
Preeclampsia diagnostics include a variety of exams and instruments that help doctors identify and treat the illness in pregnant individuals. These diagnostic methods aid in the early detection, observation, and assessment of the severity of the problem. Preeclampsia is a major source of illness and newborn mortality for both women and their offspring around the world. It can cause preterm birth and smaller-than-average newborns in pregnant women because it causes high blood pressure and a lot of protein in the urine. This dangerous pregnancy syndrome affects up to 6% of pregnancies. It is one of the most common obstetric hypertension illnesses afflicting developed and underdeveloped countries. If it is not detected at an early stage, it may cause organ failure, seizures, eclampsia, preterm birth, and even death. For instance, according to the Preeclampsia Foundation, pregnancy-induced hypertension is considered to be the global cause of 75,000 maternal and 500,000 neonatal deaths each year.
The market for preeclampsia diagnostics includes a wide variety of goods, such as diagnostic kits, reagents, laboratory supplies, equipment for monitoring blood pressure, ultrasound systems, and other associated items. The main market drivers are the global increase in preeclampsia cases, expanding prenatal care awareness, technical developments in diagnostic procedures, and the rising demand for non-invasive and precise diagnostic techniques.
Preeclampsia is a serious health issue that affects pregnant women all over the world.
Demand for non-invasive diagnostics is rising.
Both patients and medical professionals prefer non-invasive diagnostic approaches because they are more practical and have a lower risk of complications. The demand for non-invasive diagnostic techniques, including blood tests and Doppler ultrasound, is driving the market's expansion.
Restrain
The use of sophisticated diagnostic tools and tests in the diagnosis of preeclampsia might be expensive.
Acceptance by patients and ethical considerations.
Some diagnostic techniques, such as invasive procedures or frequent blood tests, may cause patient discomfort or raise ethical questions. This may affect how likely patients are to undergo diagnostic Products and how quickly the market is adopted.
Opportunity
Diagnostic procedures that can be carried out close to the patient, such as in clinics, medical offices, or even at home, are referred to as point-of-care tests.
The growth of emerging markets.
There is a substantial possibility for market expansion in emerging economies where preeclampsia is prevalent, but there might not be sufficient diagnostic infrastructure. Rising healthcare spending, growing healthcare infrastructure, and increasing maternal health awareness in these regions all present opportunities for market expansion.
Challenge
Preeclampsia has a number of underlying mechanisms and risk factors, making it a complicated and multifaceted illness.
Absence of sensitive and specific biomarkers.
Despite the fact that preeclampsia is related to a number of biomarkers, no single biomarker has been found to be particularly sensitive and specific for its detection. The creation of trustworthy and validated biomarkers is still a problem, which hinders the creation of precise diagnostic tests.
The increased demand for preeclampsia laboratory testing has decreased as a result of the Russia-Ukraine conflict. These issues have caused the healthcare industry to slow down, which has an effect on the total demand for pre-eclampsia-related tests. This has, however, opened doors for new market entrants with cutting-edge goods that can meet the demands of the market after the epidemic. Government support for healthcare and cutting-edge research may also encourage market expansion. Government healthcare organisations and businesses with cutting-edge testing procedures will both greatly benefit from this sector's expected future expansion. A lack of raw materials, a drop in fertility rates, poor reimbursement policies, and strict regulatory rules are just a few of the potential obstacles the sector may encounter.
Impact of ongoing Recession
A corporation may be impacted by a range of elements, including world events. A global company is impacted by local economic factors including inflation, recession, and competition. Additionally, due to the potential for separate or unfamiliar legal frameworks and labour markets across several jurisdictions, operating abroad may involve additional risks and obligations. Run a number of risks because of global operations, including those related to trade protection laws, tariffs, excise taxes, and other border fees on the import or export of goods or raw materials, as well as on goods supplied by particular countries. Changes in or ambiguity surrounding American or international trade legislation or tariffs may have an impact on overseas operations as well as those of our clients and suppliers.
A variety of factors, including global events, can impact a company. Local economic variables like inflation, recession, and competition have an impact on global business. Additionally, operating abroad may include additional risks and responsibilities due to the possibility of distinct or unfamiliar regulatory frameworks and labour markets spanning numerous jurisdictions. Due to international operations, we are subject to a number of risks relating to trade protection laws, tariffs, excise taxes, and other border fees on the import or export of commodities or raw materials, as well as on items supplied by specific nations.
By Test Type
Urine Analysis
Blood Tests
By Product
Equipment
Supplies
By End User
Hospitals
Diagnostic facilities
Speciality clinics
others
.png)
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
North America: Preeclampsia diagnostics are predicted to have a sizable market share in North America. The area offers a strong healthcare infrastructure, a high degree of prenatal care awareness, and cutting-edge diagnostic tools. The existence of significant market participants and ongoing R&D initiatives support market expansion in this area.
Asia-Pacific: The preeclampsia diagnostics market is anticipated to expand significantly in the Asia-Pacific region. The market is expanding as a result of elements such as a sizable population base, rising disposable income, and rising prenatal care knowledge. Market participants have a chance to capitalise on the rising demand for diagnostic equipment and technologies in emerging markets like China and India.
The major key players are Diabetomics Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd. DRG Instruments GmbH, Metabolomic Diagnostics, Thermo Fisher Scientific Holdings Inc. Sera Prognostics Inc., Shuwen Biotechnologies Co. Ltd., Siemens Healthineers AG. Baxter (U.S.) and the final reports list additional participants.
PerkinElmer Inc: In 2022, PerkinElmer, Inc. announced that a placental growth factor (PIGF) measurement using its DELFIA Xpress PIGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFit-1)/PIGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD) have been included in updated diagnostic guidance issued by the United Kingdom's National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm preeclampsia.
Shuwen Biotech Co. Ltd: A China-based innovator in the development of diagnostic products, announced in 2020 that PerkinElmer, Inc. would distribute Shuwen's ground-breaking preeclampsia diagnostic test in more than 100 nations worldwide, accounting for more than 120 million pregnancies annually.
| Report Attributes | Details |
| Market Size in 2022 | US$ 1.07 Bn |
| Market Size by 2030 | US$ 1.24 Bn |
| CAGR | CAGR of 2.4% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Test Type (Urine Analysis, Blood Tests) • By Product (Equipment, Supplies) • By End User (Hospitals, Diagnostic facilities, Speciality clinics, and others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Diabetomics Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd. DRG Instruments GmbH, Metabolomic Diagnostics, Thermo Fisher Scientific Holdings Inc. Sera Prognostics Inc., Shuwen Biotechnologies Co. Ltd., Siemens Healthineers AG. Baxter |
| Key Drivers | • Preeclampsia is a serious health issue that affects pregnant women all over the world. • Demand for non-invasive diagnostics is rising. |
| Market Opportunities | • Diagnostic procedures that can be carried out close to the patient, such as in clinics, medical offices, or even at home, are referred to as point-of-care tests. • The growth of emerging markets. |
The Preeclampsia Diagnostics Market is to grow at 2.4% Over the Forecast Period 2023-2030.
Ans: The Preeclampsia Diagnostics Market size was valued at USD 1.04 Billion in 2022
Ans: The Preeclampsia Diagnostics Market is to Hit USD 1.25 Billion by 2030.
Ans: Measurements of blood pressure are frequently used as a preeclampsia screening method.
Ans: Diabetomics Inc., PerkinElmer Inc., F. Hoffmann-La Roche Ltd. DRG Instruments GmbH, Metabolomic Diagnostics, Thermo Fisher Scientific Holdings Inc. Sera Prognostics Inc., Shuwen Biotechnologies Co. Ltd., Siemens Healthineers AG. Baxter (U.S.)
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1Impact of the Ukraine-Russia War
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
4.3 Supply Demand Gap Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global Human Insulin Market Segmentation, By Test Type
8.1 Urine Analysis
8.2 Blood Tests
9. Preeclampsia Diagnostics Market Segmentation, By Product
9.1 Equipment
9.2 Supplies
10. Preeclampsia Diagnostics Market Segmentation By End User
10.1 Hospitals
10.2 Diagnostic facilities
10.3 Speciality clinics
10.4 Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Preeclampsia Diagnostics Market by Country
11.2.2North America Preeclampsia Diagnostics Market by Test Type
11.2.3 North America Preeclampsia Diagnostics Market by Product
11.2.4 North America Preeclampsia Diagnostics Market by End User
11.2.5 USA
11.2.5.1 USA Preeclampsia Diagnostics Market by Test Type
11.2.5.2 USA Preeclampsia Diagnostics Market by Product
11.2.5.3 USA Preeclampsia Diagnostics Market by End User
11.2.6 Canada
11.2.6.1 Canada Preeclampsia Diagnostics Market by Test Type
11.2.6.2 Canada Preeclampsia Diagnostics Market by Product
11.2.6.3 Canada Preeclampsia Diagnostics Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Preeclampsia Diagnostics Market by Test Type
11.2.7.2 Mexico Preeclampsia Diagnostics Market by Product
11.2.7.3 Mexico Preeclampsia Diagnostics Market by End User
11.8 Europe
11.8.1 Europe Preeclampsia Diagnostics Market by Country
11.8.2 Europe Preeclampsia Diagnostics Market by Test Type
11.8.3 Europe Preeclampsia Diagnostics Market by Product
11.8.4 Europe Preeclampsia Diagnostics Market by End User
11.8.6 Germany
11.8.6.1 Germany Preeclampsia Diagnostics Market by Test Type
11.8.6.2 Germany Preeclampsia Diagnostics Market by Product
11.8.6.3 Germany Preeclampsia Diagnostics Market by End User
11.8.7 UK
11.8.7.1 UK Preeclampsia Diagnostics Market by Test Type
11.8.7.2 UK Preeclampsia Diagnostics Market by Product
11.8.7.3 UK Preeclampsia Diagnostics Market by End User
11.8.8 France
11.8.8.1 France Preeclampsia Diagnostics Market by Test Type
11.8.8.2 France Preeclampsia Diagnostics Market by Product
11.8.8.3 France Preeclampsia Diagnostics Market by End User
11.9.9 Italy
11.3.9.1 Italy Preeclampsia Diagnostics Market by Test Type
11.3.9.2 Italy Preeclampsia Diagnostics Market by Product
11.3.9.3 Italy Preeclampsia Diagnostics Market by End User
11.3.10 Spain
11.3.10.1 Spain Preeclampsia Diagnostics Market by Test Type
11.3.10.2 Spain Preeclampsia Diagnostics Market by Product
11.3.10.3 Spain Preeclampsia Diagnostics Market by End User
11.3.11 The Netherlands
11.3.11.1 Netherlands Preeclampsia Diagnostics Market by Test Type
11.3.11.2 Netherlands Preeclampsia Diagnostics Market by Product
11.3.11.3 Netherlands Preeclampsia Diagnostics Market by End User
11.3.12 Rest of Europe
11.3.11.1 Rest of Europe Preeclampsia Diagnostics Market by Test Type
11.3.11.2 Rest of Europe Preeclampsia Diagnostics Market by Product
11.3.11.3 Rest of Europe Preeclampsia Diagnostics Market by End User
11.4 Asia-Pacific
11.4.1 Asia Pacific Preeclampsia Diagnostics Market by Country
11.4.2 Asia Pacific Preeclampsia Diagnostics Market by Test Type
11.4.3 Asia Pacific Preeclampsia Diagnostics Market by Product
11.4.4Asia Pacific Preeclampsia Diagnostics Market by End User
11.4.6 Japan
11.4.6.1 Japan Preeclampsia Diagnostics Market by Test Type
11.4.6.2 Japan Preeclampsia Diagnostics Market by Product
11.4.6.3 Japan Preeclampsia Diagnostics Market by End User
11.4.7 South Korea
11.4.7.1 South Korea Preeclampsia Diagnostics Market by Test Type
11.4.7.2 South Korea Preeclampsia Diagnostics Market by Product
11.4.7.3 South Korea Preeclampsia Diagnostics Market by End User
11.4.8 China
11.4.8.1 China Preeclampsia Diagnostics Market by Test Type
11.4.8.2 China Preeclampsia Diagnostics Market by Product
11.4.8.3 China Preeclampsia Diagnostics Market by End User
11.4.9 India
11.4.9.1 India Preeclampsia Diagnostics Market by Test Type
11.4.9.2 India Preeclampsia Diagnostics Market by Product
11.4.9.3 India Preeclampsia Diagnostics Market by End User
11.4.10 Australia
11.4.10.1 Australia Preeclampsia Diagnostics Market by Test Type
11.4.10.2 Australia Preeclampsia Diagnostics Market by Product
11.4.10.3 Australia Preeclampsia Diagnostics Market by End User
11.4.11 Rest of Asia-Pacific
11.4.11.1 APAC Preeclampsia Diagnostics Market by Test Type
11.4.11.2 APAC Preeclampsia Diagnostics Market by Product
11.4.11.3 APAC Preeclampsia Diagnostics Market by End User
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Preeclampsia Diagnostics Market by Country
11.5.2 The Middle East & Africa Preeclampsia Diagnostics Market by Test Type
11.5.3 The Middle East & Africa Preeclampsia Diagnostics Market by Product
11.5.4The Middle East & Africa Preeclampsia Diagnostics Market by End User
11.5.6 Israel
11.5.6.1 Israel Preeclampsia Diagnostics Market by Test Type
11.5.6.2 Israel Preeclampsia Diagnostics Market by End User
11.5.6.3 Israel Preeclampsia Diagnostics Market by Product
11.5.7 UAE
11.5.7.1 UAE Preeclampsia Diagnostics Market by Test Type
11.5.7.2 UAE Preeclampsia Diagnostics Market by Product
11.5.7.3 UAE Preeclampsia Diagnostics Market by End User
11.5.8 South Africa
11.5.8.1 South Africa Preeclampsia Diagnostics Market by Test Type
11.5.8.2 South Africa Preeclampsia Diagnostics Market by Product
11.5.8.3 South Africa Preeclampsia Diagnostics Market by End User
11.5.9 Rest of Middle East & Africa
11.5.9.1 Rest of Middle East & Asia Preeclampsia Diagnostics Market by Test Type
11.5.9.2 Rest of Middle East & Asia Preeclampsia Diagnostics Market by Product
11.5.9.3 Rest of Middle East & Asia Preeclampsia Diagnostics Market By End User
11.6 Latin America
11.6.1 Latin America Preeclampsia Diagnostics Market by Country
11.6.2 Latin America Preeclampsia Diagnostics Market by Test Type
11.6.3 Latin America Preeclampsia Diagnostics Market by Product
11.6.4 Latin America Preeclampsia Diagnostics Market by End User
11.6.6 Brazil11.6.6.1 Brazil Preeclampsia Diagnostics Market by Test Type
11.6.6.2 Brazil Africa Preeclampsia Diagnostics Market by Product
11.6.6.3Brazil Preeclampsia Diagnostics Market by End User
11.6.7 Argentina
11.6.7.1 Argentina Preeclampsia Diagnostics Market by Test Type
11.6.7.2 Argentina Preeclampsia Diagnostics Market by Product
11.6.7.3 Argentina Preeclampsia Diagnostics Market by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Preeclampsia Diagnostics Market by Test Type
11.6.8.2 Rest of Latin America Preeclampsia Diagnostics Market by Product
11.6.8.3 Rest of Latin America Preeclampsia Diagnostics Market by End User
12. Company profile
12.1 Diabetomics Inc.
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 PerkinElmer Inc
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 F. Hoffmann-La Roche Ltd.
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 DRG Instruments GmbH
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Metabolomic Diagnostics
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Thermo Fisher Scientific Holdings Inc
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Sera Prognostics Inc
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Shuwen Biotechnologies Co. Ltd
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Siemens Healthineers AG
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10. Baxter (U.S.)
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14. Used Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Patient Safety and Risk Management Software Market Size was valued at USD 1.78 billion in 2022, and expected to reach USD 4.26 billion by 2030, and grow at a CAGR of 11.5% over the forecast period 2023-2030.
The Healthcare Claims Management Market Size was valued at USD 13.52 billion in 2022, and is expected to reach USD 21.39 billion by 2030, and grow at a CAGR of 5.9% over the forecast period 2023-2030.
The Artificial Cornea and Corneal Implant Market size was valued at USD 459.7 Million in 2023 and is expected to reach USD 813.7 Million By 2031 and grow at a CAGR of 7.4% over the forecast period of 2024-2031.
The Medical Carts Market was estimated at USD 2.64 billion in 2022 and is poised to reach at 7.87 billion in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 16.88% for the forecast period of 2023-2030.
The Breast Cancer Therapeutics Market size was valued at USD 30.22 billion in 2022 and is expected to reach at USD 79.77 billion by 2030, and grow at a CAGR of 12.9% over the forecast period of 2023-2030.
The Advanced Wound Care Market Size was valued at USD 10.8 billion in 2023 and is expected to reach USD 15.7 billion by 2031, and grow at a CAGR of 4.8% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
